Penumbra's revenue growth has decelerated to 14.9% in 2026Q2 from 22.1% in 2025Q4, while operating margin contracted to 10.5% from 15.4% over the same period, reflecting competitive pressures and rising SG&A costs.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated to 14.9% in 2026Q2, while gross margin remained resilient at 67.9%, but operating margin contracted to 10.5% due to SG&A rising 24% year-over-year.
Penumbra has a competitive advantage in thrombectomy technology, which is a key driver of its growth and market position.
The company is capitalizing on growing international demand for its medical devices, further boosting its revenue potential.
Penumbra's stock has risen significantly, reflecting the successful execution of its growth strategy and bullish thesis.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $1.07-10.8% vs $1.20 | $410M+2.2% vs $401M |
Q3 2026 Jul 30, 2026 | $0.88-24.1% vs $1.16 | $390M+0.1% vs $390M |
Q2 2026 May 6, 2026 | $0.82-21.2% vs $1.04 | $375M+1.2% vs $370M |
Q1 2026 Feb 25, 2026 | $1.18+6.3% vs $1.11 | $385M+6.5% vs $362M |
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology.
Penumbra, Inc. (NYSE: PEN - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $321.17 and traded as high as $322.80. Penumbra shares last traded at $320.9220, with a volume of 278,513 shares. Wall Street Analysts Forecast Growth Several research
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery ALAMEDA, Calif., Oct. 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial to demonstrate a significant correlation between real-world, daily step-based activity as captured on a consumer wearable device and patient performance in the clinical 6-minute walk test.
Benchmark PEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Penumbra, Inc. (PEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $319.21 | $12.55B | 80.55 | 17.5% | 10.06% | 10.44% | — | |
| $452.80 | $159.96B | 53.84 | 20.51% | 25.54% | 16.91% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $25.17 | $4.1B | 6.49 | 8.32% | 22.01% | 20.52% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% |
Penumbra, Inc. (PEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Penumbra, Inc. (PEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 22, 2026·SEC
May 7, 2026·SEC
Get notified when PEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Penumbra, Inc. (PEN) stock FAQ — growth, dividends, profitability & financials explained
Penumbra, Inc. (PEN) reported $1.56B in revenue over the trailing twelve months. Revenue was $1.40B in fiscal year 2025. That is 1480% more than the $88.8M of fiscal year 2013.
Penumbra, Inc. (PEN) grew revenue by 17.0% over the trailing twelve months, compared with the twelve months before.
Yes. Penumbra, Inc. (PEN) earned $157.0M in net income over the trailing twelve months (a 10.1% net margin).
Penumbra, Inc. (PEN) had a return on equity (ROE) of 10.4% over the trailing twelve months. That is in line with the market's typical 10-15%.
Penumbra, Inc. (PEN) generated $200.3M in free cash flow over the trailing twelve months.
